Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yves Allory

Showing results (191-200 of 208) with videos related to

Pageof 21
Sort By:
Clinical Genitourinary Cancer|December 29, 2019
Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor GroupMarine Sroussi, Reza Elaidi, Aude Fléchon, et al.
European Urology|September 11, 2013
Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcomeYves Allory, Willemien Beukers, Ana Sagrera, et al.
BMC Biology|February 20, 2024
Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routineCélia Dupain, Tom Gutman, Elodie Girard, et al.
Clinical Genitourinary Cancer|October 4, 2021
Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) TrialStéphane Culine, Valentin Harter, Gwenaelle Gravis, et al.
European Urology Focus|January 19, 2021
Prognostic Impact of pT3 Subclassification in a Multicentre Cohort of Patients with Urothelial Carcinoma of the Renal Pelvicalyceal System Undergoing Radical Nephroureterectomy: A Propensity Score-weighted Analysis After Central Pathology ReviewThomas Seisen, Andrea Mari, Riccardo Campi, et al.
Bladder Cancer (Amsterdam, Netherlands)|August 12, 2024
Multi-Center Assessment of Lymph-Node Density and Nodal-Stage to Predict Disease-Specific Survival in Patients with Bladder Cancer Treated by Radical CystectomyErik J van Gennep, Francesco Claps, Peter J Bostrom, et al.
European Urology|September 30, 2019
A Consensus Molecular Classification of Muscle-invasive Bladder CancerAurélie Kamoun, Aurélien de Reyniès, Yves Allory, et al.
The Lancet Regional Health. Europe|November 24, 2025
Management and survival of patients with cancer of unknown primary discussed by a French national multidisciplinary tumour board: a retrospective analysisCélia Dupain, Nicolas Jacquin, Aurélien Latouche, et al.
Der Pathologe|January 5, 2021
[Molecular pathology of urogenital tumors : Recommendations from the 2019 International Society of Urological Pathology (ISUP) Consensus Conference]Oliver Hommerding, Yves Allory, Pedram Argani, et al.
Nature Genetics|September 8, 2015
SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomasFrancois Le Loarer, Sarah Watson, Gaelle Pierron, et al.
Pageof 21

Showing results (191-200 of 208) with videos related to

Sort By:
Pageof 21
Clinical Genitourinary Cancer|December 29, 2019
Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor GroupMarine Sroussi, Reza Elaidi, Aude Fléchon, et al.
European Urology|September 11, 2013
Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcomeYves Allory, Willemien Beukers, Ana Sagrera, et al.
BMC Biology|February 20, 2024
Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routineCélia Dupain, Tom Gutman, Elodie Girard, et al.
Clinical Genitourinary Cancer|October 4, 2021
Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) TrialStéphane Culine, Valentin Harter, Gwenaelle Gravis, et al.
European Urology Focus|January 19, 2021
Prognostic Impact of pT3 Subclassification in a Multicentre Cohort of Patients with Urothelial Carcinoma of the Renal Pelvicalyceal System Undergoing Radical Nephroureterectomy: A Propensity Score-weighted Analysis After Central Pathology ReviewThomas Seisen, Andrea Mari, Riccardo Campi, et al.
Bladder Cancer (Amsterdam, Netherlands)|August 12, 2024
Multi-Center Assessment of Lymph-Node Density and Nodal-Stage to Predict Disease-Specific Survival in Patients with Bladder Cancer Treated by Radical CystectomyErik J van Gennep, Francesco Claps, Peter J Bostrom, et al.
European Urology|September 30, 2019
A Consensus Molecular Classification of Muscle-invasive Bladder CancerAurélie Kamoun, Aurélien de Reyniès, Yves Allory, et al.
The Lancet Regional Health. Europe|November 24, 2025
Management and survival of patients with cancer of unknown primary discussed by a French national multidisciplinary tumour board: a retrospective analysisCélia Dupain, Nicolas Jacquin, Aurélien Latouche, et al.
Der Pathologe|January 5, 2021
[Molecular pathology of urogenital tumors : Recommendations from the 2019 International Society of Urological Pathology (ISUP) Consensus Conference]Oliver Hommerding, Yves Allory, Pedram Argani, et al.
Nature Genetics|September 8, 2015
SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomasFrancois Le Loarer, Sarah Watson, Gaelle Pierron, et al.
Pageof 21